




The relative strengths and weaknesses of Enanta Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Enanta Pharmaceuticals INC compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 88% points. The greatest weakness of Enanta Pharmaceuticals INC is the variable Research and Development, reducing the Economic Capital Ratio by 19% points.

The company's Economic Capital Ratio, given in the ranking table, is 348%, being 103% points above the market average of 245%.

Input Variable	Value in 1000 USD	Output Variable	Value in 1000 USD
Assets, Current	311,713	Assets	375,410
Cost of Goods Sold	0	Liabilities	54,076
Intangible Assets	0	Expenses	209,571
Liabilities, Current	29,827	Revenues	86,160
Liabilities, Non-Current	22,826	Stockholders Equity	321,334
Other Assets	57,524	Net Income	-121,755
Other Compr. Net Income	-3,342	Comprehensive Net Income	-123,426
Other Expenses	-433	BaseVar	365,108
Other Liabilities	1,423	ECR before LimitedLiability	269%
Other Net Income	1,656	Economic Capital Ratio	348%
Other Revenues	86,160		
Property and Equipment	6,173		
Research and Development	164,522		
Selling, General and Administrative Expense	45,482		